Breaking News
December 16, 2017 - Research uncovers mechanism implicated in defective function of tumor-associated dendritic cells
December 16, 2017 - OncoBreak: Stubborn Racial Disparities; Paid Medical Leave & Chemo; DIY Gene Tests
December 16, 2017 - Critical link between obesity and diabetes has been identified
December 16, 2017 - Transfusion dependence reduces access to high-quality end-of-life care for leukemia patients
December 16, 2017 - Porvair and Suzhou Tianlong Bio to develop epigenetic analysis technologies
December 16, 2017 - FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade
December 16, 2017 - Morning Break: Trump to Get Check-Up; Cancerous Transplant; Death Knell for MIPS?
December 16, 2017 - First transcatheter implant for diastolic heart failure successful
December 16, 2017 - ‘Sushi-like’ nanodiscs provide structural snapshots of misfolding proteins
December 16, 2017 - Inherited gene variation may be to blame for poor survival of patients with early-onset breast cancer
December 16, 2017 - Sign-up deadline is Friday, but some people may get extra time
December 16, 2017 - Higher Booze Taxes Might Pay Off for Public Health
December 16, 2017 - Regular Activity in Midlife Spares Joints in Women
December 16, 2017 - Rain May Not Cause Achy Joints After All: MedlinePlus Health News
December 16, 2017 - MedDiet adherence doesn’t affect acute heart failure mortality
December 16, 2017 - HKBU experts develop new generation of smart anti-cancer drug molecules
December 16, 2017 - Chronic Kidney Disease Audit finds wide variations in coding of CKD patients in primary care
December 16, 2017 - Scientists use nanoparticles to fight Mucoviscidosis
December 16, 2017 - Increasing physical activity decreases risk of death from lymphoma
December 16, 2017 - Fear compromises the health, well-being of immigrant families, survey finds
December 16, 2017 - Rejected antibiotic candidate could be worth a second look, research finds
December 16, 2017 - Is Nation on the Right Track to Combat Opioid Crisis?
December 16, 2017 - Arthritis No Longer Just a Disease of the Old: MedlinePlus Health News
December 16, 2017 - Family members without inherited mutation have increased risk of melanoma
December 16, 2017 - Active surveillance proposed as first-line approach to manage patients with low-risk PMC of the thyroid
December 16, 2017 - Patients’ life values affect their attendance at medical treatment for pelvic-floor dysfunction
December 16, 2017 - Experts consider hazards of antibiotic resistances to be high
December 16, 2017 - Study finds erectile dysfunction as risk factor for early cardiovascular disease
December 16, 2017 - Amber-tinted glasses may reduce insomnia severity
December 16, 2017 - Arthritis Drug Seen Lowering GvHD Risk
December 16, 2017 - Atoh1, a potential Achilles’ heel of Sonic Hedgehog medulloblastoma
December 15, 2017 - Cornell engineers develop new method to measure vital signs using radio waves
December 15, 2017 - Rutgers studies highlight need for salon clients, workers to protect themselves from health risks
December 15, 2017 - FDA Approves Nucala (mepolizumab) for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome)
December 15, 2017 - Morning Break: CVS Buying Aetna; Uterus Transplant Baby; Your Brain on Drugs, Redux
December 15, 2017 - Social phobia linked to autism and schizophrenia
December 15, 2017 - Timestrip technology helping to prevent missed vaccinations
December 15, 2017 - Researchers win NIH grants for Alzheimer’s research on Amish resilience and rapid onset
December 15, 2017 - Mitochondrial error-correction mechanism essential for energy production of cells
December 15, 2017 - New report reveals steep rise in lung disease admissions to emergency departments during winter
December 15, 2017 - Study finds social stigma as barrier to successful treatment of children with HIV in Ethiopia
December 15, 2017 - Health Tip: Keep Gift-Giving Stress Under Wraps
December 15, 2017 - Long Stoppage of Bisphosphonates Tied to More Fractures
December 15, 2017 - Triglycerides Test: MedlinePlus Lab Test Information
December 15, 2017 - Study shows interventions, though few, can be effective for students with high-functioning autism
December 15, 2017 - Higher blood sugar during first trimester of pregnancy increases child’s risk of congenital heart defect
December 15, 2017 - Study tests accuracy of laboratory-developed cancer tests and FDA-approved companion diagnostics
December 15, 2017 - Extracellular vesicles can be used to effectively delay progression of kidney damage
December 15, 2017 - Targeted lung cancer treatments may benefit smokers and non-smokers alike
December 15, 2017 - Sugary-drink warning labels may help decrease obesity and overweight prevalence
December 15, 2017 - Coarse particulate matter exposure linked to increased asthma risk in children
December 15, 2017 - OCT Angio Gains Ground: Ophthalmology Times
December 15, 2017 - Flu Can Have Dangerous Domino Effect on Older Adults: MedlinePlus Health News
December 15, 2017 - A daily cup of hot tea may lower glaucoma risk
December 15, 2017 - New blood test accurately forecasts advanced heart failure patients’ survival after surgery
December 15, 2017 - Study finds improvements in survivals rates of individuals with kidney failure
December 15, 2017 - Rare gene mutation gives rise to low sensitivity to pain
December 15, 2017 - Older Women Do Well with New Breast Cancer Drugs
December 15, 2017 - Joint damage in healthy military recruits may mimic spondyloarthropathies
December 15, 2017 - Researchers examine link between tumor mutational burden and response to immune checkpoint therapy
December 15, 2017 - Nanotextured surfaces kill bacteria without harming mammalian cells
December 15, 2017 - Ketamine more effective than common sedative in reducing suicidal thoughts
December 15, 2017 - Scientists engineer light-emitting plant
December 15, 2017 - Medicare fails to recover hundreds of millions of dollars in lab overcharges
December 15, 2017 - IPM begins first clinical trial of vaginal rings to prevent HIV in women
December 15, 2017 - Telemedicine for addiction treatment? Picture remains fuzzy
December 15, 2017 - Genetic variations may help identify people at high-risk for chronic pain after surgery
December 15, 2017 - Intersect ENT Announces FDA Approval of Sinuva (mometasone furoate) Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
December 15, 2017 - Learning the Lessons of FluMist
December 15, 2017 - Study shows brain structures make some people resilient to Alzheimer’s disease
December 15, 2017 - UQ researchers create new and improved version of ‘love hormone’
December 15, 2017 - Anti-stress compounds provide new treatment approach for diabetes and obesity
December 15, 2017 - Survey finds extremely high rate of mortality from sepsis in ICUs
December 15, 2017 - Study provides insights into molecular mechanisms regulating cellular fate of SCCs
December 15, 2017 - Researchers identify previously unknown functions of natural killer cells in the womb
December 15, 2017 - Tech at Bedtime May Mean Heavier Kids
December 15, 2017 - Meta-Analysis: Hearing Loss Linked to Dementia in Elderly
December 15, 2017 - Second Phase 3 study results for LMTX published
December 15, 2017 - Researchers team up to identify vulnerabilities of lethal parasite
December 15, 2017 - Experts call for more action on gambling-related research and treatment
PCSK9 inhibitor offers clinical benefit to patients with peripheral artery disease

PCSK9 inhibitor offers clinical benefit to patients with peripheral artery disease

image_pdfDownload PDFimage_print

Patients with peripheral artery disease (PAD) are at high risk of heart attack, stroke and cardiovascular death. In addition, PAD patients can suffer major adverse limb events, such as acute limb ischemia – the equivalent of a heart attack in the leg – that can lead to limb loss. Managing PAD is challenging for patients and physicians alike – despite best available treatment including high-intensity statins, risk of cardiovascular and limb events remains high. With few clinical trials focused on patients with PAD, physicians must often extrapolate from studies in broader populations with atherosclerosis about the best treatment approach for these patients. Unfortunately, few of these studies have characterized limb risk and fewer have demonstrated benefits of preventive therapies in reducing this risk. A new sub-analysis of the FOURIER clinical trial, however, now offers information on the safety and effectiveness of giving the PCSK9 inhibitor evolocumab on top of statin therapy to this high-risk population. At the 2017 American Heart Association Scientific Sessions, Marc Bonaca, MD, MPH, investigator at the TIMI Study Group and director of the Aortic Disease Center at Brigham and Women’s Hospital, presented results from the sub-analysis, which are published simultaneously in Circulation.

“Whenever trials like FOURIER demonstrate benefit of a therapy in a broad population, we then want to understand the efficacy and safety in subpopulations to help clinicians understand which patients are going to derive the greatest absolute benefit. We’ve found that several sub-groups of patients respond well to evolocumab, but it’s especially encouraging to see these results for patients with PAD since this is a population at heightened cardiovascular risk and there are few therapies that modify limb risk,” said Bonaca. “We see that adding evolocumab can make a big difference for these patients.”

The team analyzed data from more than 3,600 trial participants, half of whom had no history of a heart attack or stroke. Evolocumab reduced risk of a future cardiovascular event for patients with or without PAD. Because patients with PAD are at especially high risk of a heart attack or stroke, these patients had a higher absolute risk reduction (3.5% PAD, 1.6% no PAD) of a cardiovascular event. In addition, evolocumab reduced their risk of a major adverse limb event by about half, compared to PAD patients who received the placebo. Among patients with PAD and no history of a heart attack or stroke, evolocumab reduced risk of a cardiovascular or adverse limb event by 6 percent over 2.5 years. Researchers report that the number needed to treat (NNT) – that is, how many patients would need to be prescribed the drug for 2.5 years to prevent an adverse event – is as low as 16 for this patient population. The team found no offsetting safety concerns.

Bonaca will present PAD findings as part of a Clinical Trials Update at the Scientific Sessions. Several other AHA Scientific Sessions related to FOURIER will be presented by BWH investigators. These include a second Clinical Trials Update presented by Marc Sabatine, MD, analyzing the clinical benefit of evolocumab in different subgroups of patients with a history of heart attacks, finding that those who are at higher risk – including those closer to their most recent heart attack, with multiple prior heart attacks or with multivessel disease – also reap greater relative and absolute risk reduction from the treatment. BWH investigators will also present oral presentations on the efficacy of evolocumab on different types of myocardial infractions, such as STEMI. In addition, investigators will present on the efficacy of evolocumab in reducing total cardiovascular events. Most cardiovascular trials only take into account the first cardiovascular event a patient goes on to experience, but many patients who experience a non-fatal heart attack will experience additional events. Taking these later events into account, evolocumab prevented double the number of events, compared with first events only. Finally, investigators will also present a poster on the application of the TIMI Risk Score for stable ischemic heart disease to FOURIER.

“As we continue to analyze the FOURIER data, we gain greater insight into the patients who enjoy the most substantial clinical benefits from intensive LDL-C lowering with the PCSK9 inhibitor evolocumab,” said Sabatine.

Evolocumab is a member of a new class of cholesterol lowering drugs known as PCSK9 inhibitors that have emerged as an effective treatment for drastically lowering LDL cholesterol beyond what is possible with statin therapy alone. Previous research demonstrated that evolocumab effectively reduces LDL cholesterol by approximately 60 percent. The FOURIER trial (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk) was designed to determine whether evolocumab, when added to statin therapy, would reduce adverse cardiovascular events.

FOURIER was designed in a collaboration between the Executive Committee and the trial sponsor, Amgen, which manufactures evolocumab and provided a research grant to the TIMI Study Group at BWH. The TIMI Study Group conducted all data analyses presented in the paper. Sabatine and the TIMI Study Group receive research grants from various pharmaceutical companies that produce other lipid-lowering therapies and Sabatine reports receiving honoraria from Amgen and various pharmaceutical companies that produce other lipid-lowering therapies.

Source:

http://www.brighamandwomens.org/

Tagged with:

About author

Related Articles